Organization | Chengdu Institute of Biological Products Co.,Ltd.

Chengdu Institute of Biological Products Co.,Ltd. Report issue

Government Phase 2 Phase 3 Phase 4

Founded: Chengdu China (1958)

Organization Overview

First Clinical Trial

2013

NCT02062281

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Chengdu Institute of Biological Products Co.,Ltd.

Active Ingredients

Drugs in Phase 4 Trials (10)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (4 trials)

acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia) (2 trials)

covax-19 (2 trials)

inactivated influenza vaccine (4 trials)

Inactivated polio virus - Enhanced (IPOL) (1 trial)

inactivated sabin strain polio virus (1 trial)

live oral poliovirus type 1, 2 and 3 (Trivalent oral polio vaccine - Sabin) (1 trial)

measles, mumps, and rubella vaccine (MMR) (1 trial)

multi-valent pneumococcal conjugate vaccine (1 trial)

tivantinib (1 trial)

Drugs in Phase 3 Trials (1)

11-valent recombinant human papilloma virus vaccine (3 trials)

Drugs in Phase 2 Trials (1)

human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Influenza, Human (Phase 4)

Papillomavirus Infections (Phase 2)

Pneumococcal Infections (Phase 4)

Pneumonia (Phase 4)

Pneumonia, Pneumococcal (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 10
# of Trial APIs: 12